Coherus to acquire Surface Oncology

16 June 2023
coherus_large

Aiming to boost its immune-oncology pipeline, Coherus BioSciences (Nasdaq: CHRS) today announced it will acquire Surface Oncology (Nasdaq: SURF), with the news sending the share of the latter roaring up more than 16% to $0.86. Coherus stock, on the other hand, fell as much as 18.2% to $4.41.

Surface Oncology is a clinical-stage I-O company developing next-generation immunotherapies that target the tumor microenvironment.

The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel interleukin (IL)-27-targeted antibody currently being evaluated in Phase II clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase I/II study as a monotherapy in patients with advanced solid tumors.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Biotechnology